U 100766

Each antimicrobial agent developed for clinical use during the past 60 years has ultimately encountered problems with the… Expand

Gram-positive (GP) cocci, mainly methicillin-resistant staphylococci, are the most frequent pathogens involved in central nervous… Expand

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This… Expand

This randomized, double-blind, multicenter trial compared the efficacy and safety of linezolid, an oxazolidinone, with those of… Expand

The in-vitro activity of linezolid, a novel oxazolidinone, was investigated in comparison with those of amoxycillin, cefuroxime… Expand

Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein… Expand

Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2… Expand

The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity… Expand

The new oxazolidinone antimicrobial agents U100592 and U100766 demonstrated good in vitro inhibitory activity against clinical… Expand

Two new fluorinated oxazolidinones, U-100592 and U-100766, were evaluated against more than 659 gram-positive and -negative… Expand